{"prompt": "['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', 'denosumab for bone disease and corticosteroids for the symptomatic control of brain', 'metastases provided the dose is stable before and during the study and they were started at', 'least 4 weeks prior to beginning study treatment.', 'Subsequent therapies for cancer', 'Details of first and subsequent therapies for cancer and/or details of surgery for the treatment', 'of the cancer, after discontinuation of treatment, will be collected. Reasons for starting', 'subsequent anti-cancer therapies including access to other PARP inhibitors or investigational', 'drugs will be collected and included in the exploratory assessments of OS.', '8.3.1', 'Medications that may NOT be administered', 'No other chemotherapy, immunotherapy, hormonal therapy or other novel agent is to be', 'permitted while the patient is receiving study medication.', '8.4', 'Treatment compliance', 'Patients will utilize a Pill Diary throughout the duration of the study to ensure compliance', 'with treatment.', '9.', 'ETHICAL AND REGULATORY REQUIREMENTS', '9.1', 'Ethical conduct of the study', 'The study will be performed in accordance with ethical principles that have their origin in the', 'Declaration of Helsinki and are consistent with ICH/Good Clinical Practice, and applicable', 'regulatory requirements Subject data protection.', '9.2', 'Ethics and regulatory review', 'The local IRB must review and approval the protocol and informed consent prior to study', 'activation. The IRB must comply with applicable local and national laws and regulations,', 'including protections against conflicts of interest. Prior to site activation, the following', 'regulatory items must be completed:', 'Protocol is signed and understood by Principal Investigator', \"Investigator's Brochure or product labeling, if applicable, is reviewed and\", 'understood by Principal Investigator and maintained in a file', 'Protocol, protocol amendments, and informed consent forms are approved by IRB', 'and documentation of IRB name and address and approval are maintained on file', 'with the Principal Investigator', '9.3', 'Informed consent', 'Written informed consent will be obtained by the study Investigator or a study sub-', 'Investigator working on this study. An explanation of the nature of study, its purpose,', 'procedures involved, expected duration, potential risks and benefits will be provided to each', 'participant by the treating physician (i.e., Sub-Investigator, Principal Investigator) or the', '69(93)', 'Printed on 3/25/202']['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', 'research nurse. Each participant will be informed that participation in the study is voluntary', 'and that he may withdraw from the study at any time, and that withdrawal of consent will not', 'affect his subsequent medical treatment. Participants will be allowed time needed to make an', 'informed decision. Participants will be encouraged to ask questions about the study and the', 'consent before signing the consent form. Original signed consent forms will be filed in each', \"patient's research chart, while each patient will receive a copy of the consent document. No\", 'patient will enter the study before his informed consent has been obtained.', 'The Research Coordinator and Principal Investigator (Michael Schweizer, MD) will be', 'responsible for reviewing the consent forms and verifying eligibility. Once it has been', 'confirmed that a new candidate has provided consent and is eligible to participate in the study,', 'the patient will be registered and assigned a unique study identification number.', '9.4', 'Changes to the protocol and informed consent form', 'Any changes to the protocol or consent will be made in the form of an amendment and must', 'be approved by the IRB before implementation. These changes may only be made by the', 'Principal Investigator (i.e., Michael Schweizer, MD).', '10.', 'STUDY MANAGEMENT', '10.1', 'Training of study site personnel', 'Prior to opening this study for accrual, each participating site will be required to have a Site', 'Initiation Visit (SIV). The SIV will involve a presentation by the Principal Investigator to', 'review the protocol in detail. The SIV should be attended (in person or virtually) by the', 'Principal Investigator, study coordinator, investigational drug services representative and any', 'other sub-investigators. If any of the aforementioned personnel are unable to attend the SIV,', 'the participating site will be responsible for distributing the protocol and SIV presentation for', 'review. Training should be documented on delegation logs at each participating site.', '10.2', 'Monitoring of the study', 'Trial monitoring will be in accordance with the Fred Hutchinson Cancer Research Center', '(FHCRC)/University of Washington Cancer Consortium Institutional Data and Safety', 'Monitoring Plan. Under the provisions of this plan, FHCRC Clinical Research Support', 'coordinates data and compliance monitoring conducted by consultants, contract research', 'organizations, or FHCRC employees unaffiliated with the conduct of the study. Independent', 'monitoring visits occur at specified intervals determined by the assessed risk level of the study', 'and the findings of previous visits per the institutional DSMP.', 'In addition, protocols are reviewed at least annually and as needed by the Consortium Data', 'and Safety Monitoring Committee (DSMC), FHCRC Scientific Review Committee (SRC) and', 'the FHCRC/University of Washington Cancer Consortium Institutional Review Board (IRB).', 'The review committees evaluate accrual, adverse events, stopping rules, and adherence to the', '70(93)', 'Printed on 3/25/202']\n\n###\n\n", "completion": "END"}